Synaptogenix Inc (SNPX)

[frontiers]

SFW -- the original Ph 2B trial protocol was as follows:

"In this 28-week study, participants will be randomly assigned to take either one of two doses of the study drug or a placebo, administered intravenously every 2 weeks. There will be seven doses in 12 weeks. After the first 12 weeks of treatment, subjects who took bryostatin will be randomized a second time to receive either 20- or 40-microgram infusions for an additional 12 weeks (another seven treatments). Participants who took a placebo in the first phase will receive either bryostatin or continue placebo treatment for 12 weeks."

Jeffrey Bennison told me that they decided to eliminate Part 2 of the above protocol involving re-randomization and replace it with an open label extension study of the same duration -- the change was made in July 2016.They figured they would learn more from the open label extension than from re-randomization.

Is this the change you referred to in your post? Why does this change suggest to you they expect a positive outcome?